# Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation

> **NCT03417284** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 62 (actual)

## Conditions studied

- Plasma Cell Myeloma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **BIOLOGICAL:** Filgrastim-sndz
- **DRUG:** Melphalan Hydrochloride

## Key facts

- **NCT ID:** NCT03417284
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-09
- **Primary completion:** 2024-07-18
- **Final completion:** 2024-07-18
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03417284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03417284, "Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03417284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*